Ok Biotech Co Ltd (4155) - Net Assets
Based on the latest financial reports, Ok Biotech Co Ltd (4155) has net assets worth NT$2.58 Billion TWD (≈ $81.16 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$3.85 Billion ≈ $121.28 Million USD) and total liabilities (NT$1.27 Billion ≈ $40.12 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 4155 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$2.58 Billion |
| % of Total Assets | 66.92% |
| Annual Growth Rate | 21.05% |
| 5-Year Change | 51.27% |
| 10-Year Change | 172.66% |
| Growth Volatility | 23.57 |
Ok Biotech Co Ltd - Net Assets Trend (2009–2025)
This chart illustrates how Ok Biotech Co Ltd's net assets have evolved over time, based on quarterly financial data. See Ok Biotech Co Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Ok Biotech Co Ltd (2009–2025)
The table below shows the annual net assets of Ok Biotech Co Ltd from 2009 to 2025. For live valuation and market cap data, see 4155 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$2.58 Billion ≈ $81.16 Million |
+0.36% |
| 2024-12-31 | NT$2.57 Billion ≈ $80.87 Million |
+7.17% |
| 2023-12-31 | NT$2.40 Billion ≈ $75.46 Million |
+29.72% |
| 2022-12-31 | NT$1.85 Billion ≈ $58.17 Million |
+8.42% |
| 2021-12-31 | NT$1.70 Billion ≈ $53.65 Million |
-2.08% |
| 2020-12-31 | NT$1.74 Billion ≈ $54.79 Million |
+33.57% |
| 2019-12-31 | NT$1.30 Billion ≈ $41.02 Million |
+2.69% |
| 2018-12-31 | NT$1.27 Billion ≈ $39.95 Million |
+5.14% |
| 2017-12-31 | NT$1.21 Billion ≈ $38.00 Million |
+27.65% |
| 2016-12-31 | NT$944.80 Million ≈ $29.77 Million |
-0.56% |
| 2015-12-31 | NT$950.15 Million ≈ $29.94 Million |
+11.85% |
| 2014-12-31 | NT$849.48 Million ≈ $26.76 Million |
+39.34% |
| 2013-12-31 | NT$609.65 Million ≈ $19.21 Million |
+34.85% |
| 2012-12-31 | NT$452.10 Million ≈ $14.24 Million |
+49.15% |
| 2011-12-31 | NT$303.11 Million ≈ $9.55 Million |
+31.34% |
| 2010-12-31 | NT$230.78 Million ≈ $7.27 Million |
+90.34% |
| 2009-12-31 | NT$121.25 Million ≈ $3.82 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Ok Biotech Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 134.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$96.69 Million | 3.85% |
| Common Stock | NT$1.45 Billion | 57.62% |
| Other Comprehensive Income | NT$152.22 Million | 6.06% |
| Other Components | NT$816.12 Million | 32.47% |
| Total Equity | NT$2.51 Billion | 100.00% |
Ok Biotech Co Ltd Competitors by Market Cap
The table below lists competitors of Ok Biotech Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
WI Co. Ltd.
KQ:073570
|
$68.03 Million |
|
Sangsangin Investment & Securities Co Ltd
KO:001290
|
$68.05 Million |
|
Brand X Co. Ltd.
KQ:337930
|
$68.08 Million |
|
AB Science S.A
PA:AB
|
$68.09 Million |
|
24SevenOffice Scandinavia AB
ST:247
|
$67.95 Million |
|
Kula Gold Ltd
AU:KGD
|
$67.94 Million |
|
Zalatoris II Acquisition Corp.
NASDAQ:ZLSSF
|
$67.94 Million |
|
Envirosuite Limited
F:57P
|
$67.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ok Biotech Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,492,073,000 to 2,513,182,000, a change of 21,109,000 (0.8%).
- Net income of 82,449,000 contributed positively to equity growth.
- Dividend payments of 43,789,000 reduced retained earnings.
- Share repurchases of 33,308,999 reduced equity.
- Other comprehensive income increased equity by 44,997,000.
- Other factors decreased equity by 29,239,001.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$82.45 Million | +3.28% |
| Dividends Paid | NT$43.79 Million | -1.74% |
| Share Repurchases | NT$33.31 Million | -1.33% |
| Other Comprehensive Income | NT$45.00 Million | +1.79% |
| Other Changes | NT$-29.24 Million | -1.16% |
| Total Change | NT$- | 0.85% |
Book Value vs Market Value Analysis
This analysis compares Ok Biotech Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.02x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.25x to 1.02x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | NT$4.71 | NT$15.30 | x |
| 2010-12-31 | NT$6.14 | NT$15.30 | x |
| 2011-12-31 | NT$8.20 | NT$15.30 | x |
| 2012-12-31 | NT$9.66 | NT$15.30 | x |
| 2013-12-31 | NT$12.07 | NT$15.30 | x |
| 2014-12-31 | NT$13.04 | NT$15.30 | x |
| 2015-12-31 | NT$14.01 | NT$15.30 | x |
| 2016-12-31 | NT$13.86 | NT$15.30 | x |
| 2017-12-31 | NT$17.29 | NT$15.30 | x |
| 2018-12-31 | NT$15.80 | NT$15.30 | x |
| 2019-12-31 | NT$14.45 | NT$15.30 | x |
| 2020-12-31 | NT$17.06 | NT$15.30 | x |
| 2021-12-31 | NT$14.16 | NT$15.30 | x |
| 2022-12-31 | NT$13.93 | NT$15.30 | x |
| 2023-12-31 | NT$18.67 | NT$15.30 | x |
| 2024-12-31 | NT$17.02 | NT$15.30 | x |
| 2025-12-31 | NT$15.01 | NT$15.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ok Biotech Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.28%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.30%
- • Asset Turnover: 0.40x
- • Equity Multiplier: 1.53x
- Recent ROE (3.28%) is below the historical average (12.46%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 40.99% | 17.70% | 1.37x | 1.69x | NT$37.57 Million |
| 2010 | 16.35% | 9.29% | 1.25x | 1.41x | NT$14.66 Million |
| 2011 | 23.87% | 14.39% | 1.03x | 1.60x | NT$42.03 Million |
| 2012 | 21.38% | 14.72% | 0.84x | 1.72x | NT$51.47 Million |
| 2013 | 22.67% | 12.86% | 0.74x | 2.39x | NT$77.24 Million |
| 2014 | 8.40% | 11.26% | 0.45x | 1.66x | NT$-13.58 Million |
| 2015 | 11.68% | 12.96% | 0.59x | 1.52x | NT$15.95 Million |
| 2016 | 9.02% | 8.19% | 0.70x | 1.58x | NT$-9.28 Million |
| 2017 | 10.51% | 10.28% | 0.65x | 1.56x | NT$6.21 Million |
| 2018 | 12.93% | 14.40% | 0.61x | 1.48x | NT$36.52 Million |
| 2019 | 9.75% | 10.13% | 0.56x | 1.72x | NT$-3.27 Million |
| 2020 | 7.50% | 8.74% | 0.59x | 1.47x | NT$-43.13 Million |
| 2021 | 1.84% | 2.49% | 0.45x | 1.65x | NT$-139.03 Million |
| 2022 | 7.78% | 9.67% | 0.48x | 1.66x | NT$-41.00 Million |
| 2023 | 0.12% | 0.25% | 0.39x | 1.28x | NT$-236.84 Million |
| 2024 | 3.77% | 5.63% | 0.45x | 1.48x | NT$-155.23 Million |
| 2025 | 3.28% | 5.30% | 0.40x | 1.53x | NT$-168.87 Million |
Industry Comparison
This section compares Ok Biotech Co Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,101,230,111
- Average return on equity (ROE) among peers: 16.61%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ok Biotech Co Ltd (4155) | NT$2.58 Billion | 40.99% | 0.49x | $68.03 Million |
| Hi-Clearance (1788) | $2.30 Billion | 15.13% | 0.93x | $183.75 Million |
| Radiant Innovation (3373) | $1.35 Billion | 54.68% | 0.43x | $25.20 Million |
| Wellell Inc (4106) | $1.28 Billion | 16.57% | 0.29x | $74.39 Million |
| Rossmax International Ltd (4121) | $1.85 Billion | -0.36% | 1.21x | $35.33 Million |
| United Orthopedic (4129) | $2.93 Billion | 3.02% | 0.79x | $276.18 Million |
| Dynamic Medical Technologies (4138) | $1.43 Billion | 7.33% | 0.41x | $65.17 Million |
| Bioptik Technology (4161) | $717.83 Million | 6.76% | 1.11x | $43.53 Million |
| AViTA Corporation (4735) | $422.85 Million | 23.37% | 1.55x | $37.55 Million |
| TAIDOC TECHNOLOGY CORP (4736) | $6.62 Billion | 22.98% | 0.38x | $373.31 Million |
About Ok Biotech Co Ltd
OK Biotech Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of blood glucose monitoring systems and homecare healthcare devices in Taiwan, the rest of Asia, America, Africa, and Europe. The company offers nebulizers, blood glucose meters, glucometers, blood sugar meters, and blood glucose test strips. It also provides OTC hearing aids, multi-f… Read more